


Erica Pan, MD, MPH
Director and State Public Health Officer

Gavin Newsom
Governor

May 6, 2025

TO: **California Vaccines for Adults (VFA) Providers**

FROM: Robert Schechter, M.D. 
Chief, Immunization Branch
Division of Communicable Disease Control
Center for Infectious Diseases

SUBJECT: Updates from the Advisory Committee on Immunization Practices (ACIP):
2025 Adult Immunization Recommendations and April 2025 Meeting

Dear VFA Provider,

Key [updates](#) from the [2025 Adult Immunization Schedule](#) and [April 2025 ACIP Meeting](#):

RSV Vaccine: Expanded age recommendation from age 60 to 50 years

- Newly recommended for adults **50**-74 years [with certain conditions](#).
- Still recommended for all adults 75 years and older.
- [CDC encourages healthcare providers](#) to give RSV vaccine to these age groups in late summer or early fall, just prior to the RSV season.
- For adults 50-59 years, current options are Arexvy and Abrysvo; for adults ≥ 60 years, mResvia is also an option.
- Limited supplies of Abrysvo and Arexvy are available through the VFA Program.

Pneumococcal Vaccine: Changes to age recommendations; PCV21

- Newly recommended for all adults ages **50** years and older or 19-49 years with [certain conditions](#).
- PCV21 (Capvaxine) is an option to PCV20 or (PCV15 + PPSV23): See the [Pneumococcal Timing Guide](#).
- PCV21 is available through VFA during the Spring 2025 ordering cycle.
- VFA practices switching to PCV21 submit the "[Request to Change Brand](#)" form:
 - Careful consideration should be given when switching to minimize the impact on your practice.
 - A switch should be approved by the medical director or Provider of Record.
 - Educate staff on the switch and its impact on ordering, storage, administration, and documentation.
 - To prevent unnecessary wastage of existing inventory of other pneumococcal vaccines, initial requests for PCV21 may be reduced.

- As viable unused VFA doses cannot be returned, a plan to deplete excess current pneumococcal vaccine inventory via utilization or transfer to another eligible provider is required before ordering PCV21.

Fall 2025-2026 Influenza Vaccine

- Will have an updated influenza A(H3N2) component.
- Recommendations anticipated this summer.
- Solid organ transplant recipients aged 18-64 years receiving immunosuppressive medications may receive high dose, adjuvanted, standard inactivated, or recombinant influenza vaccines.

2024-2025 COVID-19 Vaccine Guidance unchanged since Fall 2024

- All adults are recommended to receive at least one dose.
- An additional dose at least 6 months after the first dose recommended for adults ages 65 years and older or 19-64 years with immunocompromising conditions: See the [COVID-19 Vaccine Timing Guide](#) and [CDC Guidance](#).
- Available through the [Bridge Access Program](#) (but not from the VFA program).
- 2025-2026 vaccine recommendations are anticipated this summer.

Meningococcal ABCWY Vaccines: Penmenvy (GSK), PENBRAYA (Pfizer)

- Not currently available through the VFA program.
- Recommended when both MenACWY and MenB vaccines are indicated at the same visit, whether for healthy persons aged 16-23 years or persons aged ≥10 years at increased risk for meningococcal disease.

Resources

Eziz.org

VFA Program Materials

- [VFA Resources Page](#)
- [2025 Program Participation Requirements At a Glance](#)
- [CDPH VFA Program Provider Agreement](#)
- [CAIR Requirement for Documenting 317 Vaccines](#)
- [Key Practice Staff Change Request Form](#)

Updated Program Eligibility Job Aids

- [Vaccine Eligibility Guidelines](#)
- [317 Eligibility Screening and Documentation Requirements](#)
- [VFA Program Eligibility Based on Insurance](#)
- [317 Eligibility Screening Record for Adults](#)

Clinical Job Aids and Tools

- [Flu and Respiratory Prevention Materials](#)
- [COVID-19 Vaccine Timing Guide](#)
- [Pneumococcal Timing Guide](#)

- [Pneumococcal Vaccine Fact Sheet](#)
- [RSV Adult Vaccine Communications Template for Providers](#)
- [Meningococcal Routine Timing Guide](#)
- [Meningococcal Routine Timing Guide for High-Risk Groups](#)

CDC Resources

- [RSV Vaccine for Older Adults Flyer](#)
- [RSV Vaccine Information Statement](#)
- [Pneumococcal Vaccine Recommendations](#)
- [Meningococcal B Vaccination Recommendations](#)